(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback